Pulmatrix announced that it has received five new patents covering PUR1800 and PUR5700, which are inhaled narrow spectrum kinase inhibitors that Pulmatrix licensed from Janssen subsidiary RespiVert in June 2017.
The new patents include two US patents (Nos. 9,884,845 B2 and 10,045,980 B2) and two European patents (Nos. 3105222 B1 and 3105223 B1) covering RV-7031, the active pharmaceutical ingredient in PUR5700, as a composition of matter and covering dry powder formulations of RV-7031. In addition, US Patent No. 9,993,478 B2 covers dry powder formulations of p38 MAP kinase inhibitors and RV-1162, the API in PUR1800.
Pulmatrix CEO Robert Clarke commented, “These granted patents for our novel anti-inflammatory narrow spectrum kinase inhibitor molecules found in our iSPERSE PUR1800 and PUR5700 formulations provide a strong intellectual property base for these programs moving forward. Granted composition of matter claims on the active pharmaceutical ingredients when combined with our enabling iSPERSE platform technology support our proprietary approach to improve outcomes in COPD and IPF patients.”
Read the Pulmatrix press release.
